Treatment for Increased Urination Without UTI or Diabetes

Initial Assessment

The American Urological Association recommends evaluating for common causes of increased urination, including overactive bladder (OAB), benign prostatic hyperplasia (BPH) in men, and stress or urgency urinary incontinence in women 3, 4
Nocturnal polyuria (production of >33% of 24-hour urine output during sleep) should be ruled out, as it may require different management 5
A frequency-volume chart (FVC) should be completed to document voiding patterns, especially for patients with nocturia (≥2 voids per night) 4

The American Urological Association recommends regulating fluid intake, especially reducing evening fluid consumption, to manage increased urination 3, 4
Dietary irritants such as caffeine, alcohol, and highly seasoned foods should be avoided to reduce symptoms 3, 2
Lifestyle changes, including weight loss for obese patients, should be implemented to manage increased urination 2, 6
A sedentary lifestyle should be avoided to reduce symptoms 3
Bladder training (gradually extending time between voids) should be implemented for patients with urgency symptoms 1, 2
Pelvic floor muscle training (PFMT) exercises should be practiced to manage urgency symptoms 2, 7

Antimuscarinic medications, such as darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium, may be considered for overactive bladder/urgency symptoms 1, 2
Alpha-blockers may be considered for men with prostatic symptoms, and 5-alpha-reductase inhibitors may be considered for men with an enlarged prostate 3, 4
Combination therapy with an alpha-blocker and antimuscarinic may be considered for men with both obstructive and storage symptoms 4

Antimuscarinics should be avoided in patients with narrow-angle glaucoma, impaired gastric emptying, or history of urinary retention 1, 2
Vaginal estrogen with or without lactobacillus probiotics may be considered for postmenopausal women 8
Post-void residual urine should be measured in elderly patients or those with risk factors for retention before starting antimuscarinic therapy 9

Treatment success should be assessed after 2-4 weeks for alpha-blockers or antimuscarinics, and after at least 3 months for 5-alpha-reductase inhibitors 3
Annual follow-up is recommended for patients with successful treatment 3
If treatment fails or symptoms worsen, patients should be referred to a urologist for specialized management 3, 1